4-Aryliden-2-Methyloxazol-5(4h)-One as a New Scaffold for Selective Reversible MAGL Inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry - United Kingdom
doi 10.3109/14756366.2015.1010530
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

4-(2-Methoxybenzylidene)-2-Phenyl-1,3-Oxazol-5(4h)-One

Acta Crystallographica Section E Structure Reports Online
2009English

Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2018English

Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors

English

Phenylpyrazolo[1,5-A]quinazolin-5(4h)-One: A Suitable Scaffold for the Development of Noncamptothecin Topoisomerase I (Top1) Inhibitors

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2013English

2-Phenyl-4-(3,4,5-Trimethoxybenzylidene)-1,3-Oxazol-5(4h)-One

Acta Crystallographica Section E Structure Reports Online
2008English

4-[2-(4-Hydroxyphenyl)ethyl]-3-Propyl-1h-1,2,4-Triazol-5(4h)-One

Acta Crystallographica Section E Structure Reports Online
2012English

2‐Phenyloxazole‐4‐carboxamide as New Scaffold for Selective Inhibition of Human Monoamine Oxidase B

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2019English

Novel PARP-1 Inhibitors Based on a 2-Propanoyl-3h-Quinazolin-4-One Scaffold

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2014English

2-Phenyl-7-(4-Pyridylmethylamino)-1,2,4-Triazolo[1,5-A][1,3,5]triazin-5(4h)-One

Acta Crystallographica Section E Structure Reports Online
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy